BioStar's Chlamydia test cleared in US:
This article was originally published in Clinica
US distribution of BioStar's Optical Immunoassay Chlamydia point-of-care test will begin this month following FDA clearance. Using endocervical samples, the test provides results in 24 minutes. Privately-held BioStar already has US clearance for its Strep A and B tests which are marketed to clinical reference and hospital laboratories in the Americas by Murex.